Avon charges
This article was originally published in The Rose Sheet
Executive Summary
Savings of approximately $15 mil. pretax in 2003 and $40 mil.-$50 mil. in 2004 will be recorded as benefit of $43.6 mil. pretax charge scheduled to be taken in third quarter, direct-seller announces Oct. 2. Charge, which is part of Avon's business transformation initiative, will cover "severance expense in the areas of organization structure and supply chain in all geographic regions," company explains. Avon also will record $7.3 mil. pretax gain in the quarter due to an adjustment in a charge recorded in fourth quarter 2001...
You may also be interested in...
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.
Aldeyra Hopes To Refile Dry Eye Drug Reproxalap Later In 2024
Following an FDA complete response letter last November, Aldeyra has agreed with the agency on a trial design to demonstrate efficacy in ocular discomfort, which the company can complete this year.
Colorado Price Cap Plan For Enbrel Draws Amgen Lawsuit; Cosentyx, Stelara ‘Affordability’ Reviews Pending
However, the state's recently formed prescription drug affordability board found Gilead’s Genvoya and Vertex’s Trikafta to be affordable.